Events and survivors according to treatment group and stage
| . | All patients . | Group . | Stage . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| A . | B (→C) . | C . | I . | II . | III . | IV + ALL CNS− . | IV + ALL CNS+ . | ||
| No. of patients | 561 | 52 | 386 (14) | 123 | 31 | 88 (3) | 278 (11) | 97 | 67 |
| Events | |||||||||
| Initial treatment failures | 11 | 0 | 6 (4) | 5 | 0 | 0 | 6 (4) | 0 | 5 |
| Toxicity-related death | 8 | 0 | 3 | 5 | 0 | 0 | 3 | 1 | 4 |
| Relapse | 27 | 1 | 18 (1) | 8 | 2 | 1 | 14 (1) | 5 | 5 |
| Late event | 6 | 0 | 4 | 2 | 0 | 0 | 4 | 1 | 1 |
| Outcome | |||||||||
| Death | 41 | 0 | 23 (5) | 18 | 0 | 1 | 20 (5) | 6 | 14 |
| Alive in CR1 | 509 | 52 | 355 (9) | 103 | 29 | 87 (3) | 251 (6) | 90 | 52 |
| Alive after event | 11 | 0 | 8 | 2 | 2 | 0 | 7 | 1 | 1 |
| . | All patients . | Group . | Stage . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| A . | B (→C) . | C . | I . | II . | III . | IV + ALL CNS− . | IV + ALL CNS+ . | ||
| No. of patients | 561 | 52 | 386 (14) | 123 | 31 | 88 (3) | 278 (11) | 97 | 67 |
| Events | |||||||||
| Initial treatment failures | 11 | 0 | 6 (4) | 5 | 0 | 0 | 6 (4) | 0 | 5 |
| Toxicity-related death | 8 | 0 | 3 | 5 | 0 | 0 | 3 | 1 | 4 |
| Relapse | 27 | 1 | 18 (1) | 8 | 2 | 1 | 14 (1) | 5 | 5 |
| Late event | 6 | 0 | 4 | 2 | 0 | 0 | 4 | 1 | 1 |
| Outcome | |||||||||
| Death | 41 | 0 | 23 (5) | 18 | 0 | 1 | 20 (5) | 6 | 14 |
| Alive in CR1 | 509 | 52 | 355 (9) | 103 | 29 | 87 (3) | 251 (6) | 90 | 52 |
| Alive after event | 11 | 0 | 8 | 2 | 2 | 0 | 7 | 1 | 1 |
Numbers in parentheses indicate nonresponders in group B after the prephase who were switched to group C regimen. They are analyzed with group B patients.
CR indicates complete remission; for other abbreviations, see Tables 1and 2.